Business
DiaMedica Therapeutics to Participate in Cantor Global Healthcare Conference
MINNEAPOLIS, September 02, 2025--DiaMedica Therapeutics Inc. (Nasdaq: DMAC), a clinical-stage biopharmaceutical company focused on developing novel treatments for preeclampsia, fetal growth restriction and acute ischemic stroke, today announced that Rick Pauls, President and CEO, and Dave Wambeke, Chief Business Officer, will participate in a fireside chat at the upcoming Cantor Global Healthcare Conference being held in New York City from September 3-5, 2025.
About this update from Diamedica Therapeutics Inc.
MINNEAPOLIS, September 02, 2025 --( BUSINESS WIRE )--DiaMedica Therapeutics Inc. (Nasdaq: DMAC), a clinical-stage biopharmaceutical company focused on developing novel treatments for preeclampsia, fetal growth restriction and acute ischemic stroke, today announced that Rick Pauls, President and CEO, and Dave Wambeke, Chief Business Officer, will participate in a fireside chat at the upcoming Cantor Global Healthcare Conference being held in New York City from September 3-5, 2025. Fireside Chat Details Date & Time: Thursday, September 4, 2025 | 9:10-9:40 am ET Location: New York Marriott Marquis - 1535 Broadway, New York, NY 10036 Moderator: Joshua Schimmer, Managing Director, Biotech Equity Research Analyst, Cantor Fitzgerald Webcast: Click here to access the live presentation Management will also be available for one-on-one meetings with investors during the conference. About DiaMedica Therapeutics Inc. DiaMedica Therapeutics Inc. is a clinical stage biopharmaceutical company committed to improving the lives of people suffering from serious ischemic diseases with a focus on preeclampsia, fetal growth restriction and acute ischemic stroke. DiaMedica’s lead candidate DM199 is the first pharmaceutically active recombinant (synthetic) form of the KLK1 protein, an established therapeutic modality in Asia for the treatment of acute ischemic stroke, preeclampsia and other vascular diseases. For more information visit the Company’s website at www.diamedica.com . View source version on businesswire.com: https://www.businesswire.com/news/home/20250902308181/en/ Contacts Scott Kellen Chief Financial Officer Phone: (763) 496-5118 [email protected] For Investor Inquiries: Mike Moyer Managing Director, LifeSci Advisors, LLC Phone: (617) 308-4306 [email protected] Media Contact: Madelin Hawtin LifeSci Communications [email protected]
View stock analysis, news, and events for Diamedica Therapeutics Inc.